![Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer | Scientific Reports Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-40954-3/MediaObjects/41598_2019_40954_Fig1_HTML.png)
Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer | Scientific Reports
![Processes | Free Full-Text | Docetaxel for Breast Cancer Treatment-Side Effects on Ocular Surface, a Systematic Review Processes | Free Full-Text | Docetaxel for Breast Cancer Treatment-Side Effects on Ocular Surface, a Systematic Review](https://pub.mdpi-res.com/processes/processes-09-01086/article_deploy/html/images/processes-09-01086-g001.png?1624434463)
Processes | Free Full-Text | Docetaxel for Breast Cancer Treatment-Side Effects on Ocular Surface, a Systematic Review
![Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose - Kenmotsu - 2015 - Cancer Science - Wiley Online Library Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose - Kenmotsu - 2015 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7fb5b65f-b95f-4179-837e-9495b3f488d1/cas12647-toc-0001-m.jpg?trick=1675798494508)
Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose - Kenmotsu - 2015 - Cancer Science - Wiley Online Library
![Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial - The Lancet Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/10efaecc-6fad-4e0b-abd7-2a6467115a9a/gr1_lrg.gif)